Work

1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2773

Authors: D. Goode, S. Keerthikumar, S. Gupta, A.M. Joshua, L. Emmett, M. Crumbaker, T. Singer, E. Lam, L. Fernandez, E. Jimenez, D. Zhang, Y. Lin, R.J. Wenstrup, A. PASAM, R. Hicks, G. Kong, A. Hamid, S.K. Sandhu

Institutions: Peter MacCallum Cancer Centre, Epic Sciences (United States), The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, The University of Melbourne

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Merck Sharp and Dohme

OpenAlex ID: W4387810279

FWCI:

Cites:

Cited by:

Related to: 10